<DOC>
	<DOCNO>NCT01787916</DOCNO>
	<brief_summary>To knowledge , trial specifically studied effect liraglutide combine basal/bolus insulin regimen type 1 diabetes cross-over , double-blind , unicentric model . Moreover , potential impact glucagon-like peptide-1 agonist measure abdominal fat ( assess CT scan ) , insulin sensitivity ( assess gold standard euglycemic-hyperinsulinemic clamp ) satiety sensation evaluate population . Hypothesis Overweight participant type 1 diabetes liraglutide/insulin treatment present improve glucose control decrease HbA1c , decrease fast mean weekly glucose concentration glycemic excursion well increase insulin sensitivity compare participant placebo/insulin treatment . Participants liraglutide/insulin treatment also present improve endothelial function , low body weight , central adipose tissue assess CT scan high satiety sensation assess visual analogue scale .</brief_summary>
	<brief_title>52 Week Trial Liraglutide Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>type 1 diabetes non smoker BMI superior equal 25 diabetes duration superior equal 5 year diabetic complication HbA1c superior equal 8.5 % cancer acute chronic pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>overweight</keyword>
	<keyword>insulin</keyword>
	<keyword>liraglutide</keyword>
</DOC>